Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, November 1st, Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.28, for a total value of $86,096.88.

Nurix Therapeutics Stock Performance

NRIX stock opened at $20.01 on Friday. Nurix Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $29.56. The business has a 50-day moving average price of $20.14 and a 200 day moving average price of $22.40.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.38% and a negative net margin of 354.85%. On average, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of recent research reports. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price objective on the stock. UBS Group began coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. dropped their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday. Stephens reissued an “overweight” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, BMO Capital Markets started coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in shares of Nurix Therapeutics by 85.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company’s stock worth $1,531,000 after acquiring an additional 31,352 shares in the last quarter. Barclays PLC raised its holdings in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares in the last quarter. FMR LLC lifted its position in shares of Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock valued at $13,188,000 after buying an additional 511,256 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at about $530,000. Finally, Franklin Resources Inc. grew its position in shares of Nurix Therapeutics by 52.4% in the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock worth $2,766,000 after buying an additional 42,315 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.